Advertisement

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Amit Sanyal, MD: A Clinician’s Perspective

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement




Jan
07
Today In Oncology
Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxane With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer
HER2-Positive Gastroesophageal Cancer Zanidatamab Plus Chemotherapy Prolongs Progression-Free Survival
Intravesical Cretostimogene Grenadenorepvec Shows Strong High-Grade Recurrence-Free Survival in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer
IMvigor011 Subgroup Analysis: Role of ctDNA in Guiding Adjuvant Treatment for Muscle-Invasive Bladder Cancer
Study Finds Patients With Colon Cancer and Obesity Receiving GLP-1 RAs Had Significantly Reduced Risk of Mortality
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo